Merck & Co., Inc. (MRK) Acquisition of Cidara Therapeutics By Merck
Merck & Co., Inc. (NYSE: MRK) FY 2025 Special/M&A Conference
Merck & Co., Inc. (MRK) Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.
Merck & Co., Inc. (NYSE: MRK) FY 2026 M&A Release
Merck & Co., Inc. (MRK) European Commission Approves KEYTRUDA® (pembrolizumab) Plus Paclitaxel ± Bevacizumab for the Treatment of Adults With PD-L1 (CPS ≥1) Platinum-Resistant Recurrent Ovarian Carcinoma Who Have Received One or Two Prior Systemic Treatment Regimens
Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release
ADVERTISEMENT
Merck & Co., Inc. (MRK) Q1 2026 Earnings Call
Merck & Co., Inc. (NYSE: MRK) Q1 2026 Earnings Conference
Merck & Co., Inc. (MRK) Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions at Eight Weeks Compared to Guideline-Recommended Oral Non-Statin Therapies When Added to Background Statins
Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release
Merck & Co., Inc. (MRK) Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction
Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release
Merck & Co., Inc. (MRK) Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Merck & Co., Inc. (NYSE: MRK) FY 2026 Other Release
ADVERTISEMENT
Merck & Co., Inc. (MRK) Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML)
Merck & Co., Inc. (NYSE: MRK) FY 2026 M&A Release